Introduction#
Shares of Bruker Corporation and 10x Genomics experienced a decline on Monday following a tweet from Microsoft’s CEO about a new AI model called GigaTIME. This model, developed in collaboration with Providence Health and the University of Washington, can predict test results from pathology slides.
Investor Concerns#
The drop in stock prices was largely driven by investor worries that the demand for spatial proteomics—an area of study focusing on the spatial distribution of proteins in tissue samples—might decrease if clinical applications are increasingly replaced by AI technology. Wolfe Research highlighted these concerns, suggesting that investors reacted too strongly given the current market landscape.
Current Usage of Spatialomics Tools#
Wolfe Research pointed out that the spatialomics tools offered by Bruker and 10x Genomics are not widely utilized in clinical settings at this time. This indicates that the sell-off may be disproportionate, especially since the underlying study related to the GigaTIME model was published several months ago, suggesting that the news is not entirely new.
Insights on GigaTIME#
The GigaTIME model employs multimodal AI to convert pathology results into spatial proteomics data. The study involved analyzing 21 different markers, including PDL-1, which plays a crucial role in immunotherapy. The AI was trained on a vast dataset of 40 million cells and tested on over 14,000 patients. However, Wolfe Research noted that the limited number of proteins assessed might not be sufficient to prove that this AI approach can replace traditional methods, which typically evaluate a broader range of markers. They characterized the development as still being in its early stages.
Conclusion#
The tumor immune microenvironment is vital for understanding cancer progression and the effectiveness of immunotherapy. While multiplex immunofluorescence is a valuable tool for assessing this environment, it is often criticized for being costly and slow, according to the study published in Cell. As the landscape of medical technology evolves, the implications of AI advancements will continue to be closely monitored.